RenalVascular Surgery
Renal Artery Stenosis
Recognise FMD vs atherosclerotic, role of revascularisation (CORAL trial), medical therapy.
Source: ESC 2018; ACC/AHA 2024
Step 1 of ~5
info
Recognise
Suspect: resistant hypertension (≥3 drugs including diuretic), accelerated/malignant hypertension, AKI on starting ACE-I/ARB, asymmetric kidney size on USS, recurrent flash pulmonary oedema, abdominal bruit, atherosclerotic disease elsewhere, age <30 (FMD), age >55 with new HTN.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Estradiol (HRT — Hormone Replacement Therapy) · Oestrogen Replacement Therapy
- Allopurinol · Xanthine Oxidase Inhibitor — Urate-lowering Therapy
- Febuxostat · Xanthine Oxidase Inhibitor — Urate-lowering Therapy
- Nicotine · Nicotine replacement therapy (NRT)
- Eliglustat · Glucosylceramide synthase inhibitor (substrate reduction therapy)
- Allopurinol · Xanthine Oxidase Inhibitor — Urate-Lowering Therapy
Pathways
- Hyperkalaemia Management · UK Kidney Association Guidelines 2020; NICE CKD Guidelines
- Rhabdomyolysis · Renal Association 2018; UpToDate 2024
- Hypocalcaemia (Adult) · Society for Endocrinology
- SIADH (Endocrine Perspective) · European Hyponatraemia Guidelines 2014
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Acute Kidney Injury (AKI) · KDIGO 2012 / NICE AKI 2019
Decision support only. Always apply local guidelines and clinical judgement.